- Home
- AGEN vs CLPR Comparison
AGEN vs CLPR Comparison
Compare AGEN & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- CLPR
- Stock Information
- Founded
- AGEN 1994
- CLPR 2015
- Country
- AGEN United States
- CLPR United States
- Employees
- AGEN N/A
- CLPR N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- CLPR Real Estate Investment Trusts
- Sector
- AGEN Health Care
- CLPR Real Estate
- Exchange
- AGEN Nasdaq
- CLPR Nasdaq
- Market Cap
- AGEN 52.6M
- CLPR 57.8M
- IPO Year
- AGEN 2000
- CLPR 2017
- Fundamental
- Price
- AGEN $2.91
- CLPR $4.02
- Analyst Decision
- AGEN Buy
- CLPR
- Analyst Count
- AGEN 4
- CLPR 0
- Target Price
- AGEN $8.00
- CLPR N/A
- AVG Volume (30 Days)
- AGEN 830.5K
- CLPR 88.2K
- Earning Date
- AGEN 05-12-2025
- CLPR 05-20-2025
- Dividend Yield
- AGEN N/A
- CLPR 9.34%
- EPS Growth
- AGEN N/A
- CLPR N/A
- EPS
- AGEN N/A
- CLPR N/A
- Revenue
- AGEN $103,463,000.00
- CLPR $148,775,000.00
- Revenue This Year
- AGEN $4.03
- CLPR N/A
- Revenue Next Year
- AGEN $5.57
- CLPR N/A
- P/E Ratio
- AGEN N/A
- CLPR N/A
- Revenue Growth
- AGEN N/A
- CLPR 7.65
- 52 Week Low
- AGEN $1.38
- CLPR $3.38
- 52 Week High
- AGEN $19.69
- CLPR $7.12
- Technical
- Relative Strength Index (RSI)
- AGEN 59.81
- CLPR 59.46
- Support Level
- AGEN $2.87
- CLPR $3.70
- Resistance Level
- AGEN $3.16
- CLPR $4.09
- Average True Range (ATR)
- AGEN 0.35
- CLPR 0.18
- MACD
- AGEN 0.02
- CLPR 0.07
- Stochastic Oscillator
- AGEN 56.25
- CLPR 75.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.